ScholarIQanswers from OpenAlex & ORCID
David E. Gerber
ResearcherPublications, citations & collaboration network
David E. Gerber is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David E. Gerber have?
ScholarIQindexed works
David E. Gerber has 571 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David E. Gerber have?
ScholarIQcitation count
David E. Gerber has 26,082 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David E. Gerber?
ScholarIQh-index
David E. Gerber has an h-index of 60 in OpenAlex.
What is the i10-index of David E. Gerber?
ScholarIQi10-index
David E. Gerber has an i10-index of 213 in OpenAlex.
What is the ORCID of David E. Gerber?
ScholarIQorcid
The ORCID for David E. Gerber is on the source record.
What is the OpenAlex record for David E. Gerber?
ScholarIQopenalex
The OpenAlex for David E. Gerber is on the source record.
What are the most-cited papers on David E. Gerber?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal Ready, David E. Gerber, Laura Q.M. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott Antonia
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q.M. Chow, Marco Angelo Burgio, Javier de Castro, Adam Płużański, Óscar Arrieta, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, M. Alonso Garcìa, David Waterhouse, Manuel Dómine, Fabrice Barlési, Scott Antonia, M Wohlleber, David E. Gerber, Grzegorz Czyżewicz, David R. Spigel, Lucio Crinò, Wilfried Eberhardt, Ang Li, S. Marimuthu, Julie R. Brahmer